Kenneth H. Sonnenfeld

May 22, 2023 | ballardspahr.com | Caryn Borg-Breen |Scott D. Marty |Margaret Bolce Brivanlou |Kenneth H. Sonnenfeld

Summary In Amgen v. Sanofi, the Supreme Court unanimously affirmed the District of Delaware and Federal Circuit findings that Amgen’s functionally defined patent claims to a class of therapeutic antibodies are invalid as lacking enablement in the specification. The decision has implications for procurement and enforcement of patents to biotechnology inventions.